Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial.

ABSTRACT:

Purpose

Alpha lipoic acid (ALA) is a nutraceutical and potent antioxidant that has shown efficacy in the retina light damage mouse model and in humans for multiple sclerosis. Our objective was to evaluate the efficacy and safety of oral ALA for the treatment of geographic atrophy (GA).

Design

Randomized, controlled, double-masked, multicenter phase 2 clinical trial of ALA versus placebo.

Participants

Participants with unilateral or bilateral GA from age-related macular degeneration.

Methods

Participants were randomized to 1200 mg daily of ALA or placebo. Fundus autofluorescence, fundus color photography, and spectral-domain OCT were conducted and best-corrected visual acuity (BCVA) was obtained at baseline and every 6 months through month 18.

Main outcome me

SUBMITTER: Kim BJ 

PROVIDER: S-EPMC7483261 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature